Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07465835 · ClinicalTrials.gov registry record · Phase 1
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
A Phase 1 study of T Cell Malignancies, sponsored by Electra Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT07465835 is a Phase 1 study of T Cell Malignancies that is actively recruiting participants, run by Electra Therapeutics. The registered enrollment target is 84 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07465835, a Phase 1 study of T Cell Malignancies, is actively recruiting participants, sponsored by Electra Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1, two-part, multicenter study to evaluate ELA026 in participants ≥18 years old with relapsed/refractory TCM following any line of prior therapy who are eligible for investigational treatments.
Conditions Studied
Interventions
- DRUG ELA026
Study Locations (1)
Michigan
- START, Midwest - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2026-02-17 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07465835
The ClinicalTrials.gov registry entry for NCT07465835 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Electra Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with T Cell Malignancies appearing as the primary indexed condition, and to 1 intervention - of which ELA026 is the first listed.
NCT07465835 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT07465835 about?
NCT07465835 is a clinical study titled "A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)". This is a Phase 1, two-part, multicenter study to evaluate ELA026 in participants ≥18 years old with relapsed/refractory TCM following any line of prior therapy who are eligible for investigational treatments.
What is the current status of trial NCT07465835?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2026-02-17. Estimated completion is 2028-12.
What conditions does trial NCT07465835 study?
This clinical trial studies the following conditions: T Cell Malignancies.
What interventions are being tested in trial NCT07465835?
The interventions under investigation include: ELA026 (DRUG).
Who is sponsoring clinical trial NCT07465835?
This trial is sponsored by Electra Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07465835 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.